Author

Pan-Yu Chen

University of California, San Francisco

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Aishwarya C. Ballapuram· 1 shared Benjamin F. CravattiD· 1 shared Benjamin J. HuangiD· 1 shared Boer Xie· 1 shared Camille J. Leung· 1 shared Carlos GuijasiD· 1 shared Catherine Choy SmithiD· 1 shared Christopher D. BooneiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aishwarya C. Ballapuram

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer

Matthew Decker, Benjamin J. Huang, Timothy B. Ware, Christopher D. Boone, Michelle Tang, Julia Ybarra, Matthew J. Sale, Rony A. Francois, Aishwarya C. Ballapuram, Katrine A. Taran, Esteban Tarazona-Guzman, Pan-Yu Chen, Marcos Armendariz, Camille J. Leung, Max Harris, , Kevin Shannon

This study validates the palmitoylation cycle as a therapeutic target in NRAS-mutant cancers by showing that inhibiting ABHD17 reduces tumor growth and synergizes with MEK inhibitors.

bioRxiv · Mar 20, 2025 · PreprintCancer Biology